trial

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

NCTId NCT01499563
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 335 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
335 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-12
Primary completion
2013-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)Risperidone

Sponsors

Intra-Cellular Therapies, Inc.Lead Sponsor

Investigators

1
Kimberly E Vanover, PhDStudy Director

Sites

8 total
Little Rock, United StatesGarden Grove, United StatesAtlanta, United StatesRockville, United StatesSt Louis, United StatesWillingboro, United StatesPhiladelphia, United StatesAustin, United States

Linked catalysts

1
Study of a Novel Antipsychotic ITI-007 in Schizophrenia — primary completion2013-08

Facts & assertions

4 sourced
Enrollment
335
Phase
PHASE2
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
Risperidone
drug
lead_sponsor
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kimberly E Vanover, PhD
person